Sjogren’s syndrome - Epidemiology Forecast - 2030

Sjogren’s syndrome - Epidemiology Forecast - 2030

  • September 2020 •
  • 100 pages •
  • Report ID: 5962314 •
  • Format: PDF
‘Sjogren’s syndrome (SS)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Sjogren’s syndrome, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Sjogren’s syndrome (SS) Disease Understanding
Sjogren’s syndrome (SS) is a chronic autoimmune disease with a specific predisposition for causing inflammation of the exocrine glands, predominantly the salivary and lacrimal glands but also including the nose, upper respiratory tract, and oropharynx and, in women, the vagina. In this, the immune system inappropriately attacks various cells that leads to activation of the various pathway, which results in inflammation. The main consequence of this inflammation is the development of sicca symptoms due to damage to salivary and tear glands, such as dryness of the mucosal surfaces, principally in the mouth and eyes. Increased levels of cytokines and chemokines and autoantibodies expressed by the epithelium of the exocrine glands (such as the salivary and lacrimal glands) lead to chronic inflammation and the eventual loss of their physiological functions.
Due to the wide variety of signs and symptoms, patients with Sjögren’s syndrome may see a diverse range of healthcare practitioners, including family physicians, ophthalmologists, ENT specialists, and dentists, at the first consultation. Thus, physicians of various specialties must be informed about current aspects of clinical manifestations of the disease, the revised classification criteria, and current treatment options.

Sjogren’s syndrome (SS) Epidemiology
The Sjogren’s syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Sjogren’s syndrome epidemiology segmented as the Diagnosed Prevalent Cases of Sjögren’s syndrome, Gender-Specific Cases of Sjögren’s syndrome, Type-Specific Cases of Sjögren’s syndrome, Severity-Specific Cases of Sjögren’s syndrome. The report includes the Prevalent scenario of Sjogren’s syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Sjogren’s syndrome (SS) Epidemiology
The epidemiology segment also provides the Sjogren’s syndrome (SS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of Sjogren’s syndrome in 7MM countries was estimated to be 3,179,223 cases in 2017.
• As per the estimates, the United States has the highest Prevalent population of Sjogren’s syndrome
• Among the EU5 countries, the UK had the highest Prevalent population of Sjogren’s syndrome. On the other hand, Spain had the lowest Prevalent population with 197,008 cases in 2017.

Scope of the Report
• Sjogren’s syndrome (SS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• Sjogren’s syndrome (SS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Sjogren’s syndrome (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Sjogren’s syndrome (SS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Sjogren’s syndrome
• The report provides the segmentation of the Sjogren’s syndrome (SS) epidemiology by Prevalent Cases of Sjogren’s syndrome (SS) in 7MM
• The report provides the segmentation of the Sjogren’s syndrome (SS) epidemiology by Type–specific, Gender–specific and Severity–specific Prevalent Cases of Sjogren’s syndrome (SS) in 7MM

Report Highlights

• 11-Year Forecast of Sjogren’s syndrome (SS) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Sjogren’s syndrome (SS)
• Prevalent Cases according to segmentation: Type-specific Prevalence of Sjogren’s syndrome (SS), Gender-specific Prevalenceof Sjogren’s syndrome (SS), Severity-specific Prevalenceof Sjogren’s syndrome (SS)
KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Sjogren’s syndrome (SS)?
• What are the key findings pertaining to Sjogren’s syndrome (SS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Sjogren’s syndrome (SS) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of Sjogren’s syndrome?
• What are the currently available treatments for Sjogren’s syndrome?

Reasons to buy
The Sjogren’s syndrome (SS) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Sjogren’s syndrome (SS) market
• Quantify patient populations in the global Sjogren’s syndrome (SS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sjogren’s syndrome (SS) therapeutics in each of the markets covered
• Understand the magnitude of Sjogren’s syndrome (SS) population by its Prevalence cases
• Understand the magnitude of Sjogren’s syndrome (SS) population by its Etiology-specific cases
• The Sjogren’s syndrome (SS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Sjogren’s syndrome (SS) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
The study conducted by Maciel et al., (2017), titled “Prevalence of Primary Sjögren’s Syndrome in a Population-Based Cohort in the United States” is the first population-based study performed in the US and study reports the first prevalence trends of Sjögren’s syndrome.
A total of 106 patients with a physician-based diagnosis of pSS were living in 2015. Among these, 86% were female, with a mean age of 64.6 (15.2) years and disease duration of 10.5 (8.4) years. Most patients (98%) complained of dry mouth, dry eyes, or both.